Seco-DUBA is a duocarmycin (DUBA) prodrug containing two hydroxyl groups, which can each be used for coupling to an antibody via a linker. Seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs)[1].
Seco-DUBA (SK-BR-3 cells; 0.0001 pM~0.01 nM; 144 hours) dose-dependent reduces cell viability and shows equally potent and efficacious as DUBA[1].Seco-DUBA causes SK-BR-3 (IC50=0.09), SK-OV-3 (IC50=0.43), and SW620 (IC50=0.09) cells to exhibit highly sensitive[1].
Seco-DUBA (89 μg/kg; i.v.) is likely converted to DUBA almost instantaneously[1].
[1]. Elgersma RC, et al. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Mol Pharm. 2015;12(6):1813-1835.
[2]. Platform Technologies in Drug Discovery and Validation